What's in Jiangsu Hansoh Pharmaceutical Co., Ltd.'s pipeline?

Jiangsu Hansoh Pharmaceutical Co., Ltd. has 57 drugs in our index: 2 marketed, 0 filed, 10 in Phase 3, 9 in Phase 2, 36 in Phase 1.

Which companies overlap with Jiangsu Hansoh Pharmaceutical Co., Ltd.'s portfolio?

Top competitors by shared drug class: GlaxoSmithKline, AstraZeneca, Hanmi Pharmaceutical Company Limited, Chia Tai Tianqing Pharmaceutical Group Co., Ltd., Eli Lilly and Company.

How do I subscribe to ongoing alerts?

Subscribe to /feed/company/jiangsu-hansoh-pharmaceutical-co-ltd.xml in any RSS reader. Every regulatory action and pipeline update lands in your feed.

Last reviewed 2026-05-17 · How we verify

Jiangsu Hansoh Pharmaceutical Co., Ltd. — Portfolio Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Jiangsu Hansoh Pharmaceutical Co., Ltd. pipeline: 2 marketed, 0 filed, 10 Phase 3, 9 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

2 marketed 0 filed 10 Phase 3 9 Phase 2 36 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

Drug	Generic	Phase	Class	Target	Area
Xgeva®	Xgeva®	marketed	RANKL inhibitor (monoclonal antibody)	RANKL (Receptor Activator of Nuclear Factor Kappa-B Ligand)	Oncology, Bone Health
ESPO	ESPO	marketed
Placebo to match PEG-Tα1	Placebo to match PEG-Tα1	phase 3
HS-20094	HS-20094	phase 3			Oncology
HS-10296	HS-10296	phase 3	FGFR inhibitor	FGFR (Fibroblast Growth Factor Receptor)	Oncology
HS-10234	HS-10234	phase 3	FGFR inhibitor	FGFR (Fibroblast Growth Factor Receptor)	Oncology
PEG-Tα1	PEG-Tα1	phase 3	Immunomodulator; pegylated peptide	T-cell maturation pathway; thymosin alpha 1 receptor	Immunology; Infectious Disease
HS-10241+ Almonertinib	HS-10241+ Almonertinib	phase 3	EGFR tyrosine kinase inhibitor (third-generation)	EGFR (Epidermal Growth Factor Receptor)	Oncology
Pemetrexed + Cisplatin /Carboplatin	Pemetrexed + Cisplatin /Carboplatin	phase 3	Antineoplastic agent	Thymidylate synthase, Dihydrofolate reductase, Glycinamide ribonucleotide formyltransferase	Oncology
PEX168(200µg)	PEX168(200µg)	phase 3	GLP-1 receptor agonist	GLP-1R (GLP-1 receptor)	Diabetes
PEX168(100µg)	PEX168(100µg)	phase 3	GLP-1 receptor agonist	GLP-1R (GLP-1 receptor)	Diabetes
pegol-Sihematide	pegol-Sihematide	phase 3	Erythropoiesis-stimulating agent	Erythropoietin receptor	Hematology

Therapeutic area mix

Oncology · 5
Diabetes · 2
Hematology · 1
Immunology; Infectious Disease · 1
Oncology, Bone Health · 1
null · 1

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

GlaxoSmithKline · 3 shared drug classes
AstraZeneca · 3 shared drug classes
Hanmi Pharmaceutical Company Limited · 2 shared drug classes
Chia Tai Tianqing Pharmaceutical Group Co., Ltd. · 2 shared drug classes
Eli Lilly and Company · 2 shared drug classes
AbbVie · 2 shared drug classes
Daewoong Pharmaceutical Co. LTD. · 2 shared drug classes
Jiangsu HengRui Medicine Co., Ltd. · 2 shared drug classes

Subscribe to ongoing alerts

Every new pipeline event for Jiangsu Hansoh Pharmaceutical Co., Ltd.:

Cite this brief

Drug Landscape (2026). Jiangsu Hansoh Pharmaceutical Co., Ltd. — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/jiangsu-hansoh-pharmaceutical-co-ltd. Accessed 2026-05-17.